https://scholars.lib.ntu.edu.tw/handle/123456789/627062
標題: | Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2 | 作者: | Finn, Richard S Yau, Thomas CHIH-HUNG HSU De Toni, Enrico N Goyal, Lipika Galle, Peter R Qin, ShuKui Rao, Sujata Sun, Fangfang Wang, Chunxiao Widau, Ryan C Zhu, Andrew X |
關鍵字: | advanced hepatocellular carcinoma (HCC); non-sorafenib; ramucirumab; α-fetoprotein | 公開日期: | 9-十二月-2022 | 出版社: | OXFORD UNIV PRESS | 卷: | 27 | 期: | 12 | 來源出版物: | The oncologist | 摘要: | Ramucirumab is indicated for patients with advanced hepatocellular carcinoma (HCC) and α-fetoprotein (AFP) ≥400 ng/mL following sorafenib. Here, we prospectively studied ramucirumab following non-sorafenib systemic therapies. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/627062 | ISSN: | 1083-7159 | DOI: | 10.1093/oncolo/oyac183 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。